By Paul Schumacker, PhD, editor, American Journal of Respiratory Cell and Molecular Biology
Follow Dr. Schumacker on Twitter @ATSRedEditor
Myeloid-derived Suppressor Cells are Necessary for Development of Pulmonary Hypertension
In their February American Journal of Respiratory Cell and Molecular Biology article, Andrew J. Bryant, MD, and co-authors report for the first time that myeloid-derived suppressor cells (MDSCs) are necessary for the development of pulmonary hypertension in murine models of the disease. The researchers found MDSCs play a central role in “coordinating the inflammatory milieu contributing to vascular remodeling” and that in pulmonary fibrosis, trafficking to the lung of a granulocytic subset of MDSCs is increased. MDSCS express high levels of the chemokine receptor CXCR2. By inhibiting CXCR2, the researchers found, vascular changes were attenuated. “Our study provides solid pre-clinical evidence for further study of CSCR2 inhibitors in prevention, and potentially treatment, of PH associated with IPF,” the authors conclude.
February Highlights
Translational Review: Noncoding RNAs, New Players in Pulmonary Medicine and Sarcoidosis
Translational Review: Airway Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease: Role of Cigarette Smoke Exposure
Myeloid-Derived Suppressor Cells are Necessary for Development of Pulmonary Hypertension
Twist1 in Hypoxia-Induced Pulmonary Hypertension through TGFβ-Smad Signaling
Transcriptional Response of Respiratory Epithelium to Nontuberculous Mycobacteria
Multi-Tissue Transcriptomics Delineates the Diversity of Airway T Cell Functions in Asthma
